Predicting the Path to Death and Helping Patients Cope with End-Stage Heart Failure
New Rochelle, NY—Congestive heart failure affects more than 5.3 million Americans, is increasing in prevalence, and is ultimately fatal, but the duration and quality of life leading up to death can be unpredictable and vary greatly. Patients and caregivers could better plan for this difficult time if they knew what to expect. Five of the most common scenarios for the last 12 months of life in end-stage heart failure are clearly described in the article "Trajectory of Illness for Patients with Congestive Heart Failure," (online.liebertpub.com/
Authors R. Kheirbek, et al. from Washington DC Veterans Affairs Medical Center and George Washington University School of Medicine, and Bay Pines Veteran Administration Healthcare System and University of South Florida Morsani College of Medicine, modeled the path to death over the preceding 12 months of 744 patients with progressive congestive heart failure. They found that about 20% of patients had an unexpected death, whereas the remaining had a gradual progression toward death.
From these models the authors identified five different trajectories, in an effort to help bring some degree of predictability to the last 12 months of life for these patients, and help them gain some control over their illness. For example, the authors concluded that it may be possible to use progression towards death over three consecutive months as a predictor of need for Hospice consults.
“Death from heart failure is the leading cause of death in the United States," says Charles F. von Gunten, MD, PhD, Editor-in-Chief of Journal of Palliative Medicine and Clinical Professor of Medicine, University of California, San Diego. "It is high time that, like death from cancer, we plan for the future rather than being surprised when it happens."
About the Journal
Journal of Palliative Medicine (http://www.liebertpub.com/
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Population Health Management, AIDS Patient Care and STDs, and Briefings in Palliative, Hospice, and Pain Medicine & Management, a weekly e-News Alert. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc., publishers website (http://www.liebertpub.com).